Last reviewed · How we verify

Galantamine oral solution

Xian-Janssen Pharmaceutical Ltd. · FDA-approved active Small molecule Quality 2/100

Galantamine oral solution is a Small molecule drug developed by Xian-Janssen Pharmaceutical Ltd.. It is currently FDA-approved. Also known as: placebo, Razadyne, Razadyne ER, Formerly known as Reminyl.

At a glance

Generic nameGalantamine oral solution
Also known asplacebo, Razadyne, Razadyne ER, Formerly known as Reminyl
SponsorXian-Janssen Pharmaceutical Ltd.
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Galantamine oral solution

What is Galantamine oral solution?

Galantamine oral solution is a Small molecule drug developed by Xian-Janssen Pharmaceutical Ltd..

Who makes Galantamine oral solution?

Galantamine oral solution is developed and marketed by Xian-Janssen Pharmaceutical Ltd. (see full Xian-Janssen Pharmaceutical Ltd. pipeline at /company/xian-janssen-pharmaceutical-ltd).

Is Galantamine oral solution also known as anything else?

Galantamine oral solution is also known as placebo, Razadyne, Razadyne ER, Formerly known as Reminyl.

What development phase is Galantamine oral solution in?

Galantamine oral solution is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing